SMS Pharmaceuticals Board of Directors
Get the latest insights into the leadership at SMS Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Thirumalesh Tumma | Company Secretary & Compliance Officer |
| Ramesh Babu Potluri | Chairman & Managing Director |
| Shravan Kudaravalli | Non Executive Independent Director |
| Sarvepalli Srinivas | Non Executive Independent Director |
| Shanti Sree Bolleni | Non Executive Independent Director |
| Vamsi Krishna Potluri | Whole Time Director |
| Trilok Potluri | Non Independent & Non Executive Director |
| Sunkara Venkata Satya Shiva Prasad | Non Independent & Non Executive Director |
| Suresh Kumar Gangavarapu | Non Executive Independent Director |
SMS Pharmaceuticals FAQs
The board at SMS Pharmaceuticals consists of experienced professionals, including Thirumalesh Tumma, Ramesh Babu Potluri , and others, overseeing the company’s strategic and corporate governance.
Directors at SMS Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Thirumalesh Tumma is the current chairman at SMS Pharmaceuticals.
Executive directors at SMS Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, SMS Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At SMS Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
SMS Pharmaceuticals Associated Pages
